Extended follow-up of a 108-patient RCT in locally advanced gastric or GOJ cancer: perioperative toripalimab plus chemotherapy vs chemotherapy alone gave 3-year EFS of 74.7% vs 56.2% (HR 0.51) and 3-year OS of 81.3% vs 72.2% (HR 0.45).
RCTn = 108
Nie et al. Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial